株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオシミラーの市場規模:製品別、用途別、製造業者別、技術別業界分析レポート、地域別見通し、潜在的用途、価格動向、競合市場シェアおよび予測

Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025

発行 Global Market Insights Inc. 商品コード 862161
出版日 ページ情報 英文 600 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.65円で換算しております。
バイオシミラーの市場規模:製品別、用途別、製造業者別、技術別業界分析レポート、地域別見通し、潜在的用途、価格動向、競合市場シェアおよび予測 Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025
出版日: 2019年05月14日 ページ情報: 英文 600 Pages
概要

当レポートでは、世界のバイオシミラー市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査方法

第2章 エグゼクティブサマリー

第3章 業界概要

  • 業界セグメンテーション
  • 業界動向
  • 影響因子
    • 成長促進因子
    • 成長阻害因子
  • 成長可能性分析
  • 法規制動向
  • 償還動向
  • 市場分析
  • 米国のバイオシミラーに対する保険による補償
  • バイオシミラー訴訟動向
  • 製品パイプライン分析
  • バイオシミラー認可シナリオ
  • 特許失効シナリオ
  • 業界の発展
  • ファクター分析
  • 国別分析
  • 市場成功因子
  • バイオシミラー薬使用に関する国際的政策
  • ポーターズ分析
  • 競合環境
  • PESTEL分析

第4章 製品別市場

  • 市場シェア
  • 組み換え非グリコシル化プロテイン
  • 組み換えグリコシル化プロテイン

第5章 用途別市場

  • 市場シェア
  • 血液学
  • 腫瘍
  • 自己免疫疾患
  • 成長ホルモン欠乏
  • 糖尿病
  • その他

第6章 製造業者別市場

  • 市場シェア
  • 研究開発・製造受託サービス
  • インハウス

第7章 技術別市場

  • 市場シェア
  • 組み換えDNA技術
  • モノクローナル抗体

第8章 地域別市場

  • 市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 企業プロファイル

図表

Data Tables

  • TABLE 1. Biosimilars industry 360 Degree synopsis, 2014 - 2025
  • TABLE 2. Global biosimilars market, 2014 - 2018 (USD Million)
  • TABLE 3. Global biosimilars market, 2019 - 2025 (USD Million)
  • TABLE 4. Global biosimilars market, by product, 2014-2018 (USD Million)
  • TABLE 5. Global biosimilars market, by product, 2019-2025 (USD Million)
  • TABLE 6. Global biosimilars market, by application, 2014-2018 (USD Million)
  • TABLE 7. Global biosimilars market, by application, 2019-2025 (USD Million)
  • TABLE 8. Global biosimilars market, by manufacturer, 2014-2018 (USD Million)
  • TABLE 9. Global biosimilars market, by manufacturer, 2019-2025 (USD Million)
  • TABLE 10. Global biosimilars market, by technology, 2014-2018 (USD Million)
  • TABLE 11. Global biosimilars market, by technology, 2019-2025 (USD Million)
  • TABLE 12. Global biosimilars market, by region, 2014 - 2018 (USD Million)
  • TABLE 13. Global biosimilars market, by region, 2019 - 2025 (USD Million)
  • TABLE 14. Industry impact forces
  • TABLE 15. Total addressable patient population for certolizumab, by autoimmune disease 2019 - 2024
  • TABLE 16. Total addressable patient population for certolizumab, by autoimmune disease 2025 - 2030
  • TABLE 17. Total addressable patient population for certolizumab, by Crohn's disease 2019 - 2024
  • TABLE 18. Total addressable patient population for certolizumab, by Crohn's disease 2025 - 2030
  • TABLE 19. Total addressable patient population for certolizumab, by rheumatoid arthritis 2019 - 2024
  • TABLE 20. Total addressable patient population for certolizumab, by rheumatoid arthritis 2025 - 2030
  • TABLE 21. Total addressable patient population for certolizumab, by psoriatic arthritis 2019 - 2024
  • TABLE 22. Total addressable patient population for certolizumab, by psoriatic arthritis 2025 - 2030
  • TABLE 23. Total addressable patient population for certolizumab, by ankylosing spondylitis, 2019 - 2024
  • TABLE 24. Total addressable patient population for certolizumab, by ankylosing spondylitis, 2025 - 2030
  • TABLE 25. Total addressable patient population for romiplostim, by thrombocytopenia, 2019 - 2024
  • TABLE 26. Total addressable patient population for romiplostim, by thrombocytopenia, 2025 - 2030
  • TABLE 27. Example of reimbursement in U.S. (ASP methodology)
  • TABLE 28. Example of reimbursement in major Europe countries
  • TABLE 29. U.S. biosimilars insurance coverage, 2018
  • TABLE 30. Amgen biosimilar product pipeline analysis
  • TABLE 31. Biocon biosimilar product pipeline analysis
  • TABLE 32. Boehringer Ingelheim biosimilar product pipeline analysis
  • TABLE 33. Celltrion biosimilar product pipeline analysis
  • TABLE 34. Coherus BioSciences biosimilar product pipeline analysis
  • TABLE 35. Dr. Reddy's Laboratories biosimilar product pipeline analysis
  • TABLE 36. Lupin biosimilar product pipeline analysis
  • TABLE 37. Merck biosimilar product pipeline analysis
  • TABLE 38. Novartis (Sandoz) biosimilar product pipeline analysis
  • TABLE 39. Pfizer biosimilar product pipeline analysis
  • TABLE 40. Samsung Bioepis biosimilar product pipeline analysis
  • TABLE 41. Teva Pharmaceutical biosimilar product pipeline analysis
  • TABLE 42. Zydus Cadila biosimilar product pipeline analysis
  • TABLE 43. U.S. biosimilar approval scenario
  • TABLE 44. Canada biosimilar approval scenario
  • TABLE 45. Europe biosimilar approval scenario
  • TABLE 46. Japan biosimilar approval scenario
  • TABLE 47. India biosimilar approval scenario
  • TABLE 48. South Korea biosimilar approval scenario
  • TABLE 49. Australia biosimilar approval scenario
  • TABLE 50. New Zealand biosimilar approval scenario
  • TABLE 51. Biosimilars approved in Singapore
  • TABLE 52. Biosimilars approved in Malaysia
  • TABLE 53. Biologics patent expiry scenario
  • TABLE 54. International policies on use of biosimilar drugs
  • TABLE 55. Recombinant non-glycosylated proteins market size, by region, 2014 - 2018 (USD Million)
  • TABLE 56. Recombinant non-glycosylated proteins market size, by region, 2019 - 2025 (USD Million)
  • TABLE 57. Human growth hormone market size, by region, 2014 - 2018 (USD Million)
  • TABLE 58. Human growth hormone market size, by region, 2019 - 2025 (USD Million)
  • TABLE 59. Granulocyte colony-stimulating factor (Filgrastim) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 60. Granulocyte colony-stimulating factor (Filgrastim) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 61. Insulin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 62. Insulin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 63. Interferon market size, by region, 2014 - 2018 (USD Million)
  • TABLE 64. Interferon market size, by region, 2019 - 2025 (USD Million)
  • TABLE 65. Alfa market size, by region, 2014 - 2018 (USD Million)
  • TABLE 66. Alfa market size, by region, 2019 - 2025 (USD Million)
  • TABLE 67. Beta market size, by region, 2014 - 2018 (USD Million)
  • TABLE 68. Beta market size, by region, 2019 - 2025 (USD Million)
  • TABLE 69. Recombinant glycosylated proteins market size, by region, 2014 - 2018 (USD Million)
  • TABLE 70. Recombinant glycosylated proteins market size, by region, 2019 - 2025 (USD Million)
  • TABLE 71. Erythropoietin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 72. Erythropoietin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 73. Alfa market size, by region, 2014 - 2018 (USD Million)
  • TABLE 74. Alfa market size, by region, 2019 - 2025 (USD Million)
  • TABLE 75. Zeta market size, by region, 2014 - 2018 (USD Million)
  • TABLE 76. Zeta market size, by region, 2019 - 2025 (USD Million)
  • TABLE 77. Monoclonal antibodies. market size, by region, 2014 - 2018 (USD Million)
  • TABLE 78. Monoclonal antibodies. market size, by region, 2019 - 2025 (USD Million)
  • TABLE 79. Infliximab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 80. Infliximab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 81. Rituximab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 82. Rituximab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 83. Adalimumab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 84. Adalimumab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 85. Trastuzumab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 86. Trastuzumab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 87. Bevacizumab market size, by region, 2014 - 2018 (USD Million)
  • TABLE 88. Bevacizumab market size, by region, 2019 - 2025 (USD Million)
  • TABLE 89. Etanercept market size, by region, 2014 - 2018 (USD Million)
  • TABLE 90. Etanercept market size, by region, 2019 - 2025 (USD Million)
  • TABLE 91. Follitropin. market size, by region, 2014 - 2018 (USD Million)
  • TABLE 92. Follitropin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 93. Alfa market size, by region, 2014 - 2018 (USD Million)
  • TABLE 94. Alfa market size, by region, 2019 - 2025 (USD Million)
  • TABLE 95. Beta market size, by region, 2014 - 2018 (USD Million)
  • TABLE 96. Beta market size, by region, 2019 - 2025 (USD Million)
  • TABLE 97. Low molecular weight heparin market size, by region, 2014 - 2018 (USD Million)
  • TABLE 98. Low molecular weight heparin market size, by region, 2019 - 2025 (USD Million)
  • TABLE 99. Hematology market size, by region, 2014 - 2018 (USD Million)
  • TABLE 100. Hematology market size, by region, 2019 - 2025 (USD Million)
  • TABLE 101. Neutropenia market size, by region, 2014 - 2018 (USD Million)
  • TABLE 102. Neutropenia market size, by region, 2019 - 2025 (USD Million)
  • TABLE 103. Anemia market size, by region, 2014 - 2018 (USD Million)
  • TABLE 104. Anemia market size, by region, 2019 - 2025 (USD Million)
  • TABLE 105. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 106. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 107. Oncology market size, by region, 2014 - 2018 (USD Million)
  • TABLE 108. Oncology market size, by region, 2019 - 2025 (USD Million)
  • TABLE 109. Lung cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 110. Lung cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 111. Brain cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 112. Brain cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 113. Breast cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 114. Breast cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 115. Cervical cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 116. Cervical cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 117. Colorectal cancer market size, by region, 2014 - 2018 (USD Million)
  • TABLE 118. Colorectal cancer market size, by region, 2019 - 2025 (USD Million)
  • TABLE 119. Leukemia market size, by region, 2014 - 2018 (USD Million)
  • TABLE 120. Leukemia market size, by region, 2019 - 2025 (USD Million)
  • TABLE 121. Non-Hodgkin lymphoma. (NHL) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 122. Non-Hodgkin lymphoma. (NHL) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 123. Chronic lymphocytic leukemia (CLL) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 124. Chronic lymphocytic leukemia (CLL) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 125. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 126. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 127. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 128. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 129. Autoimmune disease market size, by region, 2014 - 2018 (USD Million)
  • TABLE 130. Autoimmune disease market size, by region, 2019 - 2025 (USD Million)
  • TABLE 131. Arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 132. Arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 133. Rheumatoid arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 134. Rheumatoid arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 135. Psoriatic arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 136. Psoriatic arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 137. Juvenile arthritis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 138. Juvenile arthritis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 139. Ankylosing spondylitis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 140. Ankylosing spondylitis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 141. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 142. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 143. Inflammatory bowel disease market size, by region, 2014 - 2018 (USD Million)
  • TABLE 144. Inflammatory bowel disease market size, by region, 2019 - 2025 (USD Million)
  • TABLE 145. Ulcerative colitis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 146. Ulcerative colitis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 147. Crohn's disease market size, by region, 2014 - 2018 (USD Million)
  • TABLE 148. Crohn's disease market size, by region, 2019 - 2025 (USD Million)
  • TABLE 149. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 150. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 151. Psoriasis market size, by region, 2014 - 2018 (USD Million)
  • TABLE 152. Psoriasis market size, by region, 2019 - 2025 (USD Million)
  • TABLE 153. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 154. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 155. Growth hormone deficiency market size, by region, 2014 - 2018 (USD Million)
  • TABLE 156. Growth hormone deficiency market size, by region, 2019 - 2025 (USD Million)
  • TABLE 157. Diabetes market size, by region, 2014 - 2018 (USD Million)
  • TABLE 158. Diabetes market size, by region, 2019 - 2025 (USD Million)
  • TABLE 159. Others market size, by region, 2014 - 2018 (USD Million)
  • TABLE 160. Others market size, by region, 2019 - 2025 (USD Million)
  • TABLE 161. Contract research and manufacturing services market size, by region, 2014 - 2018 (USD Million)
  • TABLE 162. Contract research and manufacturing services market size, by region, 2019 - 2025 (USD Million)
  • TABLE 163. In-house market size, by region, 2014 - 2018 (USD Million)
  • TABLE 164. In-house market size, by region, 2019 - 2025 (USD Million)
  • TABLE 165. Recombinant DNA technology (rDNA technology) market size, by region, 2014 - 2018 (USD Million)
  • TABLE 166. Recombinant DNA technology (rDNA technology) market size, by region, 2019 - 2025 (USD Million)
  • TABLE 167. Monoclonal antibodies (MAb) technology market size, by region, 2014 - 2018 (USD Million)
  • TABLE 168. Monoclonal antibodies (MAb) technology market size, by region, 2019 - 2025 (USD Million)
  • TABLE 169. North America biosimilars market size, by country, 2014-2018 (USD Million)
  • TABLE 170. North America biosimilars market size, by country, 2019-2025 (USD Million)
  • TABLE 171. North America biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 172. North America biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 173. North America biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 174. North America biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 175. North America biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 176. North America biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 177. North America biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 178. North America biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 179. North America biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 180. North America biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 181. North America biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 182. North America biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 183. North America biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 184. North America biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 185. North America biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 186. North America biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 187. North America biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 188. North America biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 189. North America biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 190. North America biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 191. North America biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 192. North America biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 193. North America biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 194. North America biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 195. North America biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 196. North America biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 197. U.S. biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 198. U.S. biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 199. U.S. biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 200. U.S. biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 201. U.S. biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 202. U.S. biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 203. U.S. biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 204. U.S. biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 205. U.S. biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 206. U.S. biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 207. U.S. biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 208. U.S. biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 209. U.S. biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 210. U.S. biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 211. U.S. biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 212. U.S. biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 213. U.S. biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 214. U.S. biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 215. U.S. biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 216. U.S. biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 217. U.S. biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 218. U.S. biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 219. U.S. biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 220. U.S. biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 221. U.S. biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 222. U.S. biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 223. Canada biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 224. Canada biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 225. Canada biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 226. Canada biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 227. Canada biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 228. Canada biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 229. Canada biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 230. Canada biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 231. Canada biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 232. Canada biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 233. Canada biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 234. Canada biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 235. Canada biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 236. Canada biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 237. Canada biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 238. Canada biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 239. Canada biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 240. Canada biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 241. Canada biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 242. Canada biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 243. Canada biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 244. Canada biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 245. Europe biosimilars market size, by country, 2014-2018 (USD Million)
  • TABLE 246. Europe biosimilars market size, by country, 2019-2025 (USD Million)
  • TABLE 247. Europe biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 248. Europe biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 249. Europe biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 250. Europe biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 251. Europe biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 252. Europe biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 253. Europe biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 254. Europe biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 255. Europe biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 256. Europe biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 257. Europe biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 258. Europe biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 259. Europe biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 260. Europe biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 261. Europe biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 262. Europe biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 263. Europe biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 264. Europe biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 265. Europe biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 266. Europe biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 267. Europe biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 268. Europe biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 269. Europe biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 270. Europe biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 271. Europe biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 272. Europe biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 273. Europe biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 274. Europe biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 275. Europe biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 276. Europe biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 277. Europe biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 278. Europe biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 279. Germany biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 280. Germany biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 281. Germany biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 282. Germany biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 283. Germany biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 284. Germany biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 285. Germany biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 286. Germany biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 287. Germany biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 288. Germany biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 289. Germany biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 290. Germany biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 291. Germany biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 292. Germany biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 293. Germany biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 294. Germany biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 295. Germany biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 296. Germany biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 297. Germany biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 298. Germany biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 299. Germany biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 300. Germany biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 301. Germany biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 302. Germany biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 303. Germany biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 304. Germany biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 305. Germany biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 306. Germany biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 307. Germany biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 308. Germany biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 309. Germany biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 310. Germany biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 311. UK biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 312. UK biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 313. UK biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 314. UK biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 315. UK biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 316. UK biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 317. UK biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 318. UK biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 319. UK biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 320. UK biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 321. UK biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 322. UK biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 323. UK biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 324. UK biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 325. UK biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 326. UK biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 327. UK biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 328. UK biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 329. UK biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 330. UK biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 331. UK biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 332. UK biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 333. UK biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 334. UK biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 335. UK biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 336. UK biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 337. UK biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 338. UK biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 339. UK biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 340. UK biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 341. UK biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 342. UK biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 343. France biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 344. France biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 345. France biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 346. France biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 347. France biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 348. France biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 349. France biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 350. France biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 351. France biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 352. France biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 353. France biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 354. France biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 355. France biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 356. France biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 357. France biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 358. France biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 359. France biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 360. France biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 361. France biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 362. France biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 363. France biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 364. France biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 365. France biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 366. France biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 367. France biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 368. France biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 369. France biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 370. France biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 371. France biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 372. France biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 373. France biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 374. France biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 375. Spain biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 376. Spain biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 377. Spain biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 378. Spain biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 379. Spain biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 380. Spain biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 381. Spain biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 382. Spain biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 383. Spain biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 384. Spain biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 385. Spain biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 386. Spain biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 387. Spain biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 388. Spain biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 389. Spain biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 390. Spain biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 391. Spain biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 392. Spain biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 393. Spain biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 394. Spain biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 395. Spain biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 396. Spain biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 397. Spain biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 398. Spain biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 399. Spain biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 400. Spain biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 401. Spain biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 402. Spain biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 403. Spain biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 404. Spain biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 405. Spain biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 406. Spain biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 407. Italy biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 408. Italy biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 409. Italy biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 410. Italy biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 411. Italy biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 412. Italy biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 413. Italy biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 414. Italy biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 415. Italy biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 416. Italy biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 417. Italy biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 418. Italy biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 419. Italy biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 420. Italy biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 421. Italy biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 422. Italy biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 423. Italy biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 424. Italy biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 425. Italy biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 426. Italy biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 427. Italy biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 428. Italy biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 429. Italy biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 430. Italy biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 431. Italy biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 432. Italy biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 433. Italy biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 434. Italy biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 435. Italy biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 436. Italy biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 437. Italy biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 438. Italy biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 439. Russia biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 440. Russia biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 441. Russia biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 442. Russia biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 443. Russia biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 444. Russia biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 445. Russia biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 446. Russia biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 447. Russia biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 448. Russia biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 449. Russia biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 450. Russia biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 451. Russia biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 452. Russia biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 453. Russia biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 454. Russia biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 455. Russia biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 456. Russia biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 457. Russia biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 458. Russia biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 459. Russia biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 460. Russia biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 461. Russia biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 462. Russia biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 463. Russia biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 464. Russia biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 465. Russia biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 466. Russia biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 467. Russia biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 468. Russia biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 469. Russia biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 470. Russia biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 471. Turkey biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 472. Turkey biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 473. Turkey biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 474. Turkey biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 475. Turkey biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 476. Turkey biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 477. Turkey biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 478. Turkey biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 479. Turkey biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 480. Turkey biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 481. Turkey biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 482. Turkey biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 483. Turkey biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 484. Turkey biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 485. Turkey biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 486. Turkey biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 487. Turkey biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 488. Turkey biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 489. Turkey biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 490. Turkey biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 491. Turkey biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 492. Turkey biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 493. Turkey biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 494. Turkey biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 495. Turkey biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 496. Turkey biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 497. Turkey biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 498. Turkey biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 499. Turkey biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 500. Turkey biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 501. Turkey biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 502. Turkey biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 503. Austria biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 504. Austria biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 505. Austria biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 506. Austria biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 507. Austria biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 508. Austria biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 509. Austria biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 510. Austria biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 511. Austria biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 512. Austria biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 513. Austria biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 514. Austria biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 515. Austria biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 516. Austria biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 517. Austria biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 518. Austria biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 519. Austria biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 520. Austria biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 521. Austria biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 522. Austria biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 523. Austria biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 524. Austria biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 525. Austria biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 526. Austria biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 527. Austria biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 528. Austria biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 529. Austria biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 530. Austria biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 531. Austria biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 532. Austria biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 533. Austria biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 534. Austria biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 535. Belgium biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 536. Belgium biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 537. Belgium biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 538. Belgium biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 539. Belgium biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 540. Belgium biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 541. Belgium biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 542. Belgium biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 543. Belgium biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 544. Belgium biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 545. Belgium biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 546. Belgium biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 547. Belgium biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 548. Belgium biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 549. Belgium biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 550. Belgium biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 551. Belgium biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 552. Belgium biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 553. Belgium biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 554. Belgium biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 555. Belgium biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 556. Belgium biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 557. Belgium biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 558. Belgium biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 559. Belgium biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 560. Belgium biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 561. Belgium biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 562. Belgium biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 563. Belgium biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 564. Belgium biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 565. Belgium biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 566. Belgium biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 567. Bulgaria biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 568. Bulgaria biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 569. Bulgaria biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 570. Bulgaria biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 571. Bulgaria biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 572. Bulgaria biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 573. Bulgaria biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 574. Bulgaria biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 575. Bulgaria biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 576. Bulgaria biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 577. Bulgaria biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 578. Bulgaria biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 579. Bulgaria biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 580. Bulgaria biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 581. Bulgaria biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 582. Bulgaria biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 583. Bulgaria biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 584. Bulgaria biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 585. Bulgaria biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 586. Bulgaria biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 587. Bulgaria biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 588. Bulgaria biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 589. Bulgaria biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 590. Bulgaria biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 591. Bulgaria biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 592. Bulgaria biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 593. Bulgaria biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 594. Bulgaria biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 595. Bulgaria biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 596. Bulgaria biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 597. Bulgaria biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 598. Bulgaria biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 599. Czech Republic biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 600. Czech Republic biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 601. Czech Republic biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Mn)
  • TABLE 602. Czech Republic biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Mn)
  • TABLE 603. Czech Republic biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 604. Czech Republic biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 605. Czech Republic biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 606. Czech Republic biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 607. Czech Republic biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 608. Czech Republic biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 609. Czech Republic biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 610. Czech Republic biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 611. Czech Republic biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 612. Czech Republic biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 613. Czech Republic biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 614. Czech Republic biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 615. Czech Republic biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 616. Czech Republic biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 617. Czech Republic biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 618. Czech Republic biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 619. Czech Republic biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 620. Czech Republic biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 621. Czech Republic biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 622. Czech Republic biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 623. Czech Republic biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 624. Czech Republic biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 625. Czech Republic biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 626. Czech Republic biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 627. Czech Republic biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 628. Czech Republic biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 629. Czech Republic biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 630. Czech Republic biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 631. Denmark biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 632. Denmark biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 633. Denmark biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 634. Denmark biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 635. Denmark biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 636. Denmark biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 637. Denmark biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 638. Denmark biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 639. Denmark biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 640. Denmark biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 641. Denmark biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 642. Denmark biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 643. Denmark biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 644. Denmark biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 645. Denmark biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 646. Denmark biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 647. Denmark biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 648. Denmark biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 649. Denmark biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 650. Denmark biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 651. Denmark biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 652. Denmark biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 653. Denmark biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 654. Denmark biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 655. Denmark biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 656. Denmark biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 657. Denmark biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 658. Denmark biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 659. Denmark biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 660. Denmark biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 661. Denmark biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 662. Denmark biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 663. Finland biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 664. Finland biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 665. Finland biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 666. Finland biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 667. Finland biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 668. Finland biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 669. Finland biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 670. Finland biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 671. Finland biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 672. Finland biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 673. Finland biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 674. Finland biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 675. Finland biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 676. Finland biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 677. Finland biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 678. Finland biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 679. Finland biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 680. Finland biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 681. Finland biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 682. Finland biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 683. Finland biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 684. Finland biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 685. Finland biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 686. Finland biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 687. Finland biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 688. Finland biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 689. Finland biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 690. Finland biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 691. Finland biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 692. Finland biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 693. Finland biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 694. Finland biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 695. Greece biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 696. Greece biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 697. Greece biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 698. Greece biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 699. Greece biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 700. Greece biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 701. Greece biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 702. Greece biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 703. Greece biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 704. Greece biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 705. Greece biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 706. Greece biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 707. Greece biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 708. Greece biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 709. Greece biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 710. Greece biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 711. Greece biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 712. Greece biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 713. Greece biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 714. Greece biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 715. Greece biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 716. Greece biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 717. Greece biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 718. Greece biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 719. Greece biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 720. Greece biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 721. Greece biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 722. Greece biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 723. Greece biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 724. Greece biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 725. Greece biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 726. Greece biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 727. Hungary biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 728. Hungary biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 729. Hungary biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 730. Hungary biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 731. Hungary biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 732. Hungary biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 733. Hungary biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 734. Hungary biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 735. Hungary biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 736. Hungary biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 737. Hungary biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 738. Hungary biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 739. Hungary biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 740. Hungary biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 741. Hungary biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 742. Hungary biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 743. Hungary biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 744. Hungary biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 745. Hungary biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 746. Hungary biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 747. Hungary biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 748. Hungary biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 749. Hungary biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 750. Hungary biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 751. Hungary biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 752. Hungary biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 753. Hungary biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 754. Hungary biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 755. Hungary biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 756. Hungary biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 757. Hungary biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 758. Hungary biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 759. Ireland biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 760. Ireland biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 761. Ireland biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 762. Ireland biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 763. Ireland biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 764. Ireland biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 765. Ireland biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 766. Ireland biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 767. Ireland biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 768. Ireland biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 769. Ireland biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 770. Ireland biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 771. Ireland biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 772. Ireland biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 773. Ireland biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 774. Ireland biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 775. Ireland biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 776. Ireland biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 777. Ireland biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 778. Ireland biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 779. Ireland biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 780. Ireland biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 781. Ireland biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 782. Ireland biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 783. Ireland biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 784. Ireland biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 785. Ireland biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 786. Ireland biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 787. Ireland biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 788. Ireland biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 789. Ireland biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 790. Ireland biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 791. Netherlands biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 792. Netherlands biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 793. Netherlands biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 794. Netherlands biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 795. Netherlands biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 796. Netherlands biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 797. Netherlands biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 798. Netherlands biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 799. Netherlands biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 800. Netherlands biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 801. Netherlands biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 802. Netherlands biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 803. Netherlands biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 804. Netherlands biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 805. Netherlands biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 806. Netherlands biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 807. Netherlands biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 808. Netherlands biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 809. Netherlands biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 810. Netherlands biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 811. Netherlands biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 812. Netherlands biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 813. Netherlands biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 814. Netherlands biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 815. Netherlands biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 816. Netherlands biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 817. Netherlands biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 818. Netherlands biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 819. Netherlands biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 820. Netherlands biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 821. Netherlands biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 822. Netherlands biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 823. Norway biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 824. Norway biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 825. Norway biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 826. Norway biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 827. Norway biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 828. Norway biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 829. Norway biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 830. Norway biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 831. Norway biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 832. Norway biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 833. Norway biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 834. Norway biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 835. Norway biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 836. Norway biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 837. Norway biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 838. Norway biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 839. Norway biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 840. Norway biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 841. Norway biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 842. Norway biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 843. Norway biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 844. Norway biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 845. Norway biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 846. Norway biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 847. Norway biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 848. Norway biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 849. Norway biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 850. Norway biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 851. Norway biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 852. Norway biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 853. Norway biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 854. Norway biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 855. Romania biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 856. Romania biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 857. Romania biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 858. Romania biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 859. Romania biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 860. Romania biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 861. Romania biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 862. Romania biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 863. Romania biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 864. Romania biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 865. Romania biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 866. Romania biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 867. Romania biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 868. Romania biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 869. Romania biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 870. Romania biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 871. Romania biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 872. Romania biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 873. Romania biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 874. Romania biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 875. Romania biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 876. Romania biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 877. Romania biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 878. Romania biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 879. Romania biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 880. Romania biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 881. Romania biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 882. Romania biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 883. Romania biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 884. Romania biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 885. Romania biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 886. Romania biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 887. Slovakia biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 888. Slovakia biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 889. Slovakia biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 890. Slovakia biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 891. Slovakia biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 892. Slovakia biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 893. Slovakia biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 894. Slovakia biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 895. Slovakia biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 896. Slovakia biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 897. Slovakia biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 898. Slovakia biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 899. Slovakia biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 900. Slovakia biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 901. Slovakia biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 902. Slovakia biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 903. Slovakia biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 904. Slovakia biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 905. Slovakia biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 906. Slovakia biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 907. Slovakia biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 908. Slovakia biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 909. Slovakia biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 910. Slovakia biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 911. Slovakia biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 912. Slovakia biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 913. Slovakia biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 914. Slovakia biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 915. Slovakia biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 916. Slovakia biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 917. Slovakia biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 918. Slovakia biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 919. Slovenia biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 920. Slovenia biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 921. Slovenia biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 922. Slovenia biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 923. Slovenia biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 924. Slovenia biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 925. Slovenia biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 926. Slovenia biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 927. Slovenia biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 928. Slovenia biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 929. Slovenia biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 930. Slovenia biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 931. Slovenia biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 932. Slovenia biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 933. Slovenia biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 934. Slovenia biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 935. Slovenia biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 936. Slovenia biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 937. Slovenia biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 938. Slovenia biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 939. Slovenia biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 940. Slovenia biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 941. Slovenia biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 942. Slovenia biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 943. Slovenia biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 944. Slovenia biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 945. Slovenia biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 946. Slovenia biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 947. Slovenia biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 948. Slovenia biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 949. Slovenia biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 950. Slovenia biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 951. Sweden biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 952. Sweden biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 953. Sweden biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 954. Sweden biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 955. Sweden biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 956. Sweden biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 957. Sweden biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 958. Sweden biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 959. Sweden biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 960. Sweden biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 961. Sweden biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 962. Sweden biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 963. Sweden biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 964. Sweden biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 965. Sweden biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 966. Sweden biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 967. Sweden biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 968. Sweden biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 969. Sweden biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 970. Sweden biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 971. Sweden biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 972. Sweden biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 973. Sweden biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 974. Sweden biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 975. Sweden biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 976. Sweden biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 977. Sweden biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 978. Sweden biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 979. Sweden biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 980. Sweden biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 981. Sweden biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 982. Sweden biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 983. Switzerland biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 984. Switzerland biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 985. Switzerland biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 986. Switzerland biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 987. Switzerland biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 988. Switzerland biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 989. Switzerland biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 990. Switzerland biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 991. Switzerland biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 992. Switzerland biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 993. Switzerland biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 994. Switzerland biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 995. Switzerland biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 996. Switzerland biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 997. Switzerland biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 998. Switzerland biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 999. Switzerland biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1000. Switzerland biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1001. Switzerland biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1002. Switzerland biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1003. Switzerland biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1004. Switzerland biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1005. Switzerland biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1006. Switzerland biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1007. Switzerland biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1008. Switzerland biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1009. Switzerland biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1010. Switzerland biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1011. Switzerland biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1012. Switzerland biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1013. Switzerland biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1014. Switzerland biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1015. Asia Pacific biosimilars market size, by country, 2014-2018 (USD Million)
  • TABLE 1016. Asia Pacific biosimilars market size, by country, 2019-2025 (USD Million)
  • TABLE 1017. Asia Pacific biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1018. Asia Pacific biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1019. Asia Pacific biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1020. Asia Pacific biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1021. Asia Pacific biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 1022. Asia Pacific biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 1023. Asia Pacific biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1024. Asia Pacific biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1025. Asia Pacific biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1026. Asia Pacific biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1027. Asia Pacific biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1028. Asia Pacific biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1029. Asia Pacific biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 1030. Asia Pacific biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 1031. Asia Pacific biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1032. Asia Pacific biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1033. Asia Pacific biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1034. Asia Pacific biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1035. Asia Pacific biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1036. Asia Pacific biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1037. Asia Pacific biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1038. Asia Pacific biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1039. Asia Pacific biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1040. Asia Pacific biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1041. Asia Pacific biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1042. Asia Pacific biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1043. Asia Pacific biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1044. Asia Pacific biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1045. Asia Pacific biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1046. Asia Pacific biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1047. Asia Pacific biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1048. Asia Pacific biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1049. China biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1050. China biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1051. China biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1052. China biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1053. China biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 1054. China biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 1055. China biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1056. China biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1057. China biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1058. China biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1059. China biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1060. China biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1061. China biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 1062. China biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 1063. China biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1064. China biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1065. China biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1066. China biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1067. China biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1068. China biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1069. China biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1070. China biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1071. China biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1072. China biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1073. China biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1074. China biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1075. China biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1076. China biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1077. China biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1078. China biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1079. China biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1080. China biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1081. Japan biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1082. Japan biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1083. Japan biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1084. Japan biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1085. Japan biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1086. Japan biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1087. Japan biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1088. Japan biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1089. Japan biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1090. Japan biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1091. Japan biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1092. Japan biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1093. Japan biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1094. Japan biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1095. Japan biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1096. Japan biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1097. Japan biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1098. Japan biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1099. Japan biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1100. Japan biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1101. Japan biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1102. Japan biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1103. Japan biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1104. Japan biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1105. Japan biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1106. Japan biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1107. Japan biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1108. Japan biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1109. India biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1110. India biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1111. India biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1112. India biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1113. India biosimilars market size, by interferon, 2014-2018 (USD Million)
  • TABLE 1114. India biosimilars market size, by interferon, 2019-2025 (USD Million)
  • TABLE 1115. India biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1116. India biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1117. India biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1118. India biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1119. India biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1120. India biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1121. India biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 1122. India biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 1123. India biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1124. India biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1125. India biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1126. India biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1127. India biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1128. India biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1129. India biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1130. India biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1131. India biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1132. India biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1133. India biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1134. India biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1135. India biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1136. India biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1137. India biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1138. India biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1139. India biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1140. India biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1141. South Korea biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1142. South Korea biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1143. South Korea biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1144. South Korea biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1145. South Korea biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1146. South Korea biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1147. South Korea biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1148. South Korea biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1149. South Korea biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1150. South Korea biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1151. South Korea biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1152. South Korea biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1153. South Korea biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1154. South Korea biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1155. South Korea biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1156. South Korea biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1157. South Korea biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1158. South Korea biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1159. South Korea biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1160. South Korea biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1161. South Korea biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1162. South Korea biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1163. South Korea biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1164. South Korea biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1165. Australia biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1166. Australia biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1167. Australia biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1168. Australia biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1169. Australia biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1170. Australia biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1171. Australia biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1172. Australia biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1173. Australia biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1174. Australia biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1175. Australia biosimilars market size, by follitropin, 2014-2018 (USD Million)
  • TABLE 1176. Australia biosimilars market size, by follitropin, 2019-2025 (USD Million)
  • TABLE 1177. Australia biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1178. Australia biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1179. Australia biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1180. Australia biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1181. Australia biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1182. Australia biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1183. Australia biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1184. Australia biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1185. Australia biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1186. Australia biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1187. Australia biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1188. Australia biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1189. Australia biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1190. Australia biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1191. Australia biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1192. Australia biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1193. Australia biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1194. Australia biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1195. New Zealand biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1196. New Zealand biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1197. New Zealand biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1198. New Zealand biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1199. New Zealand biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1200. New Zealand biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1201. New Zealand biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1202. New Zealand biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1203. New Zealand biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1204. New Zealand biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1205. New Zealand biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1206. New Zealand biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1207. New Zealand biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1208. New Zealand biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1209. New Zealand biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1210. New Zealand biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1211. New Zealand biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1212. New Zealand biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1213. New Zealand biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1214. New Zealand biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1215. Singapore biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1216. Singapore biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1217. Singapore biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1218. Singapore biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1219. Singapore biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1220. Singapore biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1221. Singapore biosimilars market size, by monoclonal antibodies, 2014-2018 (USD Million)
  • TABLE 1222. Singapore biosimilars market size, by monoclonal antibodies, 2019-2025 (USD Million)
  • TABLE 1223. Singapore biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1224. Singapore biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1225. Singapore biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1226. Singapore biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1227. Singapore biosimilars market size, by autoimmune disease, 2014-2018 (USD Million)
  • TABLE 1228. Singapore biosimilars market size, by autoimmune disease, 2019-2025 (USD Million)
  • TABLE 1229. Singapore biosimilars market size, by arthritis, 2014-2018 (USD Million)
  • TABLE 1230. Singapore biosimilars market size, by arthritis, 2019-2025 (USD Million)
  • TABLE 1231. Singapore biosimilars market size, by inflammatory bowel disease, 2014-2018 (USD Million)
  • TABLE 1232. Singapore biosimilars market size, by inflammatory bowel disease, 2019-2025 (USD Million)
  • TABLE 1233. Singapore biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1234. Singapore biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1235. Singapore biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1236. Singapore biosimilars market size, by technology, 2019-2025 (USD Million)
  • TABLE 1237. Malaysia biosimilars market size, by product, 2014-2018 (USD Million)
  • TABLE 1238. Malaysia biosimilars market size, by product, 2019-2025 (USD Million)
  • TABLE 1239. Malaysia biosimilars market size, by recombinant non-glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1240. Malaysia biosimilars market size, by recombinant non-glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1241. Malaysia biosimilars market size, by recombinant glycosylated proteins, 2014-2018 (USD Million)
  • TABLE 1242. Malaysia biosimilars market size, by recombinant glycosylated proteins, 2019-2025 (USD Million)
  • TABLE 1243. Malaysia biosimilars market size, by erythropoietin, 2014-2018 (USD Million)
  • TABLE 1244. Malaysia biosimilars market size, by erythropoietin, 2019-2025 (USD Million)
  • TABLE 1245. Malaysia biosimilars market size, by application, 2014-2018 (USD Million)
  • TABLE 1246. Malaysia biosimilars market size, by application, 2019-2025 (USD Million)
  • TABLE 1247. Malaysia biosimilars market size, by hematology, 2014-2018 (USD Million)
  • TABLE 1248. Malaysia biosimilars market size, by hematology, 2019-2025 (USD Million)
  • TABLE 1249. Malaysia biosimilars market size, by oncology, 2014-2018 (USD Million)
  • TABLE 1250. Malaysia biosimilars market size, by oncology, 2019-2025 (USD Million)
  • TABLE 1251. Malaysia biosimilars market size, by leukemia, 2014-2018 (USD Million)
  • TABLE 1252. Malaysia biosimilars market size, by leukemia, 2019-2025 (USD Million)
  • TABLE 1253. Malaysia biosimilars market size, by manufacturer, 2014-2018 (USD Million)
  • TABLE 1254. Malaysia biosimilars market size, by manufacturer, 2019-2025 (USD Million)
  • TABLE 1255. Malaysia biosimilars market size, by technology, 2014-2018 (USD Million)
  • TABLE 1256. Malaysia biosimilars market size, by technology, 2019-2025 (USD Million)

Charts & Figures

  • FIG. 1 Market estimation and forecast methodology
  • FIG. 2 Top-down approach (demand side analysis)
  • FIG. 3 Bottom-up approach (supply side analysis)
  • FIG. 4 Industry segmentation
  • FIG. 5 Global biosimilars market, 2014 - 2025 (USD Million)
  • FIG. 6 Growth potential analysis, by product
  • FIG. 7 Growth potential analysis, by application
  • FIG. 8 Growth potential analysis, by manufacturer
  • FIG. 9 Growth potential analysis, by technology
  • FIG. 10 Total addressable patient population, by autoimmune disease, 2019 - 2030 (number of patients)
  • FIG. 11 Total addressable patient population, by Crohn's disease, 2019 - 2030 (number of patients)
  • FIG. 12 Total addressable patient population, by rheumatoid arthritis, 2019 - 2030 (number of patients)
  • FIG. 13 Total addressable patient population, by psoriatic arthritis, 2019 - 2030 (number of patients)
  • FIG. 14 Total addressable patient population, by ankylosing spondylitis, 2019 - 2030 (number of patients)
  • FIG. 15 Total addressable patient population, by thrombocytopenia, 2019 - 2030 (number of patients)
  • FIG. 16 Market analysis
  • FIG. 17 Biosimilar product authorization in U.S. and Europe, 2006 - 2018
  • FIG. 18 Biosimilar approvals, 2004 - 2018
  • FIG. 19 Factor analysis
  • FIG. 20 Key success factors
  • FIG. 21 Porter's analysis
  • FIG. 22 Strategy dashboard
  • FIG. 23 PESTEL analysis
目次
Product Code: 3328

Title:
Biosimilars Market Size By Product (Recombinant Non-Glycosylated Proteins {Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Interferon}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Follitropin, Low Molecular Weight Heparin}), By Application (Haematology {Neutropenia, Anaemia}, Oncology {Lung Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Leukaemia or Blood Cancer}, Autoimmune Disease {Arthritis, Inflammatory Bowel Disease, Psoriasis}, Growth Hormone Deficiency, Diabetes), By Manufacturer (Contract Research and Manufacturing Services, In-house), By Technology (Recombinant DNA Technology, Monoclonal Antibodies Technology) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025.

Biosimilars Market will exceed USD 69 billion by 2025; as per a new research report.

Biosimilars market is estimate to growth at a significant rate over the forecast period. Biosimilars are estimated to play a substantial role in enhancing public health issue by addressing the customer needs. It is estimated that biosimilars would result in total potential savings of around over USD 100 billion by the year 2020. Increase in demand for biosimilar drugs in order to reduce the healthcare cost will be one of the major market boosting factors.

Growing prevalence of chronic disorders across the globe, especially in developing regions of Asia Pacific and Latin America owing to rise in sedentary lifestyle among the population and growing habit of fast food consumption will result in growing number of people suffering from such diseases. Hence, increased prevalence rate in developed as well as in certain areas in developing nations will augment the demand and adoption rate of biosimilar drugs, fueling the business growth.

However, high biosimilar development cost will be one of the major reasons hampering the adoption rates in under-developed and few developing countries. It takes around 7 to 8 years and costs around USD 100 million to USD 250 million to develop a biosimilar. Hence, high cost related to biosimilar drugs development will continue to hinder market growth over the forecast timeframe.

Recombinant non-glycosylated proteins market held the majority market share in the year 2018 and is estimated to grow at around 26.1% over the estimation period. Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor (Filgrastim), insulin and interferon. Recent technological developments in high-throughput analytical techniques and cell technology will help in effective production of products resulting in enhanced sales. Also, recent launch of insulin glargine in major countries and growing demand of filgrastim will further augment the biosimilars market growth.

Application of biosimilars is highest in hematology segment resulting in major market share. The hematology segment accounted for around USD 4,552.1 million revenue in the year 2018. As per the American Society of Hematology, around 3 million American suffer from anemia. Increase in number of people suffering from blood disorders such as neutropenia, anemia etc. will boost the sales of biosimilars.

In-house manufacturing of biosimilars held around 75% market share in the year 2018 and is forecasted to grow at around 26.5% over the projection period. Several benefits offered by in-house manufacturing facilities has helped the companies to monitor and assess the production and reduce other costs of delivery and shipping. Also, several other advantages of in-house manufacturing such as flexibility and efficiency of the work will increase the operational and financial capabilities of the company. Hence, currently in-house manufacturing of biosimilar products will have major market share.

Development of biosimilars by recombinant DNA technology (rDNA technology) held over 80% market share and was valued at USD 8,123.6 million in the year 2018. Biosimilar products such as human growth hormones, insulin, erythropoietin etc. are manufactured using recombinant DNA technology. The use of rDNA technology improves the capability of the biosimilars to treat ailment immediately and efficiently. Hence, manufacturers use the recombinant DNA technology in order to manufacture biosimilar products.

U.S. dominated the North America biosimilars market and is estimated to witness significant growth at 38.1% over the forecast period. Presence of new technology, state-of-art facilities for biosimilar production, established and big pharma players market presence has resulted in the U.S. capturing majority market share of the North America biosimilars market. Also, recent biosimilar approvals by FDA in the year 2015 will result in rapid biosimilar adoption, augmenting the market growth. During the forecast years, it will witness significant growth owing to relatively low addressable needs.

Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences are some of the major industry participants operating in the global biosimilars market. Various firms are entering in less addressed and high potential geographies in order to expand their industry presence. Also, introduction and development of several biosimilar drug in developing countries by major local companies will result in augmenting the market growth.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definition
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Biosimilars industry 360 Degree synopsis, 2014 - 2025 (USD Million)
    • 2.1.1. Business trends
    • 2.1.2. Product trends
    • 2.1.3. Application trends
    • 2.1.4. Manufacturer trends
    • 2.1.5. Technology trends
    • 2.1.6. Regional trends

Chapter 3. Biosimilars Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2014 - 2025 (USD Million)
  • 3.3. Industry impact factors
    • 3.3.1. Growth drivers
      • 3.3.1.1. Emphasis on reducing healthcare cost in developed economies of Europe
      • 3.3.1.2. Cost effectiveness of biosimilars in U.S.
      • 3.3.1.3. Increase in R&D activities in the developing countries of Asia Pacific
      • 3.3.1.4. Patent expiration of biologics
      • 3.3.1.5. Rise in prevalence of chronic diseases across the globe
      • 3.3.1.6. Recent biosimilar product approvals in major countries
      • 3.3.1.7. Strong product pipeline
    • 3.3.2. Industry pitfalls & challenges
      • 3.3.2.1. High development cost of biosimilar drugs
      • 3.3.2.2. Presence of biologics and bio-betters
      • 3.3.2.3. Regulatory uncertainty
      • 3.3.2.4. Interchangeability
  • 3.4. Growth potential analysis
    • 3.4.1. By product
    • 3.4.2. By application
    • 3.4.3. By manufacturer
    • 3.4.4. By technology
  • 3.5. Total addressable market, 2019 - 2030 (Number of patients)
    • 3.5.1. Certolizumab (Autoimmune diseases)
      • 3.5.1.1. U.S.
      • 3.5.1.2. Europe
      • 3.5.1.3. Japan
      • 3.5.1.4. India
      • 3.5.1.5. Rest of World
      • 3.5.1.6. Crohn's disease
        • 3.5.1.6.1. U.S.
        • 3.5.1.6.2. Europe
        • 3.5.1.6.3. Japan
        • 3.5.1.6.4. India
        • 3.5.1.6.5. Rest of World
      • 3.5.1.7. Rheumatoid arthritis
        • 3.5.1.7.1. U.S.
        • 3.5.1.7.2. Europe
        • 3.5.1.7.3. Japan
        • 3.5.1.7.4. India
        • 3.5.1.7.5. Rest of World
      • 3.5.1.8. Psoriatic arthritis
        • 3.5.1.8.1. U.S.
        • 3.5.1.8.2. Europe
        • 3.5.1.8.3. Japan
        • 3.5.1.8.4. India
        • 3.5.1.8.5. Rest of World
      • 3.5.1.9. Ankylosing spondylitis
        • 3.5.1.9.1. U.S.
        • 3.5.1.9.2. Europe
        • 3.5.1.9.3. Japan
        • 3.5.1.9.4. India
        • 3.5.1.9.5. Rest of World
    • 3.5.2. Romiplostim (Thrombocytopenia)
      • 3.5.2.1. U.S.
      • 3.5.2.2. Europe
      • 3.5.2.3. Japan
      • 3.5.2.4. India
      • 3.5.2.5. Rest of World
  • 3.6. Regulatory landscape
    • 3.6.1. U.S.
    • 3.6.2. Canada
    • 3.6.3. Europe
    • 3.6.4. India
    • 3.6.5. Japan
    • 3.6.6. South Korea
    • 3.6.7. Australia
    • 3.6.8. Singapore
  • 3.7. Reimbursement landscape
    • 3.7.1. Europe
    • 3.7.2. Canada
    • 3.7.3. Australia
    • 3.7.4. New Zealand
  • 3.8. Market analysis
    • 3.8.1. Strength
    • 3.8.2. Weakness
    • 3.8.3. Opportunity
    • 3.8.4. Threat
  • 3.9. U.S. biosimilars insurance coverage, 2017
  • 3.10. Biosimilar litigation landscape
  • 3.11. Biosimilar product pipeline analysis
    • 3.11.1. Amgen
    • 3.11.2. Biocon
    • 3.11.3. Boehringer Ingelheim
    • 3.11.4. Celltrion
    • 3.11.5. Coherus BioSciences
    • 3.11.6. Dr. Reddy's Laboratories
    • 3.11.7. Lupin
    • 3.11.8. Merck
    • 3.11.9. Novartis (Sandoz)
    • 3.11.10. Pfizer
    • 3.11.11. Samsung Bioepis
    • 3.11.12. Teva Pharmaceutical
    • 3.11.13. Zydus Cadila
  • 3.12. Biosimilars approval scenario, 2018
    • 3.12.1. U.S.
    • 3.12.2. Canada
    • 3.12.3. Europe
    • 3.12.4. Japan
    • 3.12.5. India
    • 3.12.6. South Korea
    • 3.12.7. Australia
    • 3.12.8. New Zealand
    • 3.12.9. Singapore
    • 3.12.10. Malaysia
  • 3.13. Patent expiry scenario
  • 3.14. Biosimilars industry evolution
    • 3.14.1. U.S.
    • 3.14.2. Europe
  • 3.15. Biosimilars factor analysis
    • 3.15.1. Access
    • 3.15.2. Regulations
    • 3.15.3. Payer assessment and access
    • 3.15.4. Physician acceptance
    • 3.15.5. Patient acceptance
    • 3.15.6. Number of biosimilar approvals
  • 3.16. Biosimilars landscape - country analysis
    • 3.16.1. U.S.
    • 3.16.2. Europe
    • 3.16.3. China
    • 3.16.4. Japan
    • 3.16.5. India
    • 3.16.6. South Korea
  • 3.17. Key market success factors
  • 3.18. International policies on use of biosimilar drugs
    • 3.18.1. Interchangeability, Switching and Substitution
    • 3.18.2. Supply Side Policies
    • 3.18.3. Prescribing Incentives
  • 3.19. Porter's analysis
  • 3.20. Competitive landscape, 2017
    • 3.20.1. Strategy dashboard
  • 3.21. PESTEL analysis

Chapter 4. Biosimilars Market, By Product

  • 4.1. Global biosimilars market share by product, 2018 & 2025
  • 4.2. Recombinant Non-Glycosylated Proteins
    • 4.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.2. Human Growth Hormone
      • 4.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.3. Granulocyte Colony-Stimulating Factor (Filgrastim)
      • 4.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.4. Insulin
      • 4.2.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.2.5. Interferon
      • 4.2.5.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.2.5.2. Alfa
        • 4.2.5.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.2.5.3. Beta
        • 4.2.5.3.1. Market size, by region, 2014 - 2025 (USD Million)
  • 4.3. Recombinant Glycosylated Proteins
    • 4.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.2. Erythropoietin
      • 4.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.2.2. Alfa
        • 4.3.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.2.3. Zeta
        • 4.3.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.3. Monoclonal Antibodies
      • 4.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.2. Infliximab
        • 4.3.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.3. Rituximab
        • 4.3.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.4. Adalimumab
        • 4.3.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.5. Trastuzumab
        • 4.3.3.5.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.6. Bevacizumab
        • 4.3.3.6.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.3.7. Etanercept
        • 4.3.3.7.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.4. Follitropin
      • 4.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.4.2. Alfa
        • 4.3.4.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 4.3.4.3. Beta
        • 4.3.4.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 4.3.5. Low Molecular Weight Heparin (LMWHs)
      • 4.3.5.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 5. Biosimilars Market, By Application

  • 5.1. Global biosimilars market share by application, 2018 & 2025
  • 5.2. Hematology
    • 5.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.2.2. Neutropenia
      • 5.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.2.3. Anemia
      • 5.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.2.4. Others
      • 5.2.4.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.2. Lung Cancer
      • 5.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.3. Brain Cancer
      • 5.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.4. Breast Cancer
      • 5.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.5. Cervical Cancer
      • 5.3.5.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.6. Colorectal Cancer
      • 5.3.6.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.7. Leukemia
      • 5.3.7.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.3.7.2. Non-Hodgkin Lymphoma (NHL)
        • 5.3.7.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.3.7.3. Chronic Lymphocytic Leukemia (CLL)
        • 5.3.7.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.3.7.4. Others
        • 5.3.7.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.3.8. Others
      • 5.3.8.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.4. Autoimmune Disease
    • 5.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.2. Arthritis
      • 5.4.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.2. Rheumatoid Arthritis
        • 5.4.2.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.3. Psoriatic Arthritis
        • 5.4.2.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.4. Juvenile Arthritis
        • 5.4.2.4.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.5. Ankylosing Spondylitis
        • 5.4.2.5.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.2.6. Others
        • 5.4.2.6.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.3. Inflammatory Bowel Disease (IBD)
      • 5.4.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.3.2. Ulcerative Colitis
        • 5.4.3.2.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.3.3. Crohn's Disease
        • 5.4.3.3.1. Market size, by region, 2014 - 2025 (USD Million)
      • 5.4.3.4. Others
        • 5.4.3.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.4. Psoriasis
      • 5.4.4.1. Market size, by region, 2014 - 2025 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.5. Growth Hormone Deficiency
    • 5.5.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.6. Diabetes
    • 5.6.1. Market size, by region, 2014 - 2025 (USD Million)
  • 5.7. Others
    • 5.7.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 6. Biosimilars Market, By Manufacturer

  • 6.1. Global biosimilars market share by manufacturer, 2018 & 2025
  • 6.2. Contract Research and Manufacturing Services
    • 6.2.1. Market size, by region, 2014 - 2025 (USD Million)
  • 6.3. In-house
    • 6.3.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 7. Biosimilars Market, By Technology

  • 7.1. Global biosimilars market share by technology, 2018 & 2025
  • 7.2. Recombinant DNA Technology (rDNA technology)
    • 7.2.1. Market size, by region, 2014 - 2025 (USD Million)
  • 7.3. Monoclonal Antibodies (MAb) Technology
    • 7.3.1. Market size, by region, 2014 - 2025 (USD Million)

Chapter 8. Biosimilars Market, By Region

  • 8.1. Global biosimilars market share by region, 2018 & 2025
  • 8.2. North America
    • 8.2.1. Market size, by country, 2014 - 2025 (USD Million)
    • 8.2.2. Market size, by product, 2014 - 2025 (USD Million)
      • 8.2.2.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
      • 8.2.2.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.2.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
    • 8.2.3. Market size, by application, 2014 - 2025 (USD Million)
      • 8.2.3.1. Market size, by hematology, 2014 - 2025 (USD Million)
      • 8.2.3.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.2.3.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.2.3.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.2.3.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.2.3.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
    • 8.2.4. Market size, by manufacturer, 2014 - 2025 (USD Million)
    • 8.2.5. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.2.6. U.S.
      • 8.2.6.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.2.6.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.6.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.6.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.2.6.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.2.6.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.2.6.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.2.6.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.2.6.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.2.6.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.2.6.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.2.6.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.2.6.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.2.7. Canada
      • 8.2.7.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.2.7.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.7.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.2.7.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.2.7.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.2.7.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.2.7.2.2. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.2.7.2.2.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.2.7.2.2.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.2.7.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.2.7.4. Market size, by technology, 2014 - 2025 (USD Million)
  • 8.3. Europe
    • 8.3.1. Market size, by country, 2014 - 2025 (USD Million)
    • 8.3.2. Market size, by product, 2014 - 2025 (USD Million)
      • 8.3.2.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.3.2.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
      • 8.3.2.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.3.2.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
        • 8.3.2.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
        • 8.3.2.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
    • 8.3.3. Market size, by application, 2014 - 2025 (USD Million)
      • 8.3.3.1. Market size, by hematology, 2014 - 2025 (USD Million)
      • 8.3.3.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.3.3.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.3.3.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.3.3.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.3.3.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
    • 8.3.4. Market size, by manufacturer, 2014 - 2025 (USD Million)
    • 8.3.5. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.6. Germany
      • 8.3.6.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.6.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.6.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.6.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.6.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.6.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.6.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.6.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.6.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.6.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.6.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.6.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.6.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.6.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.6.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.6.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.7. UK
      • 8.3.7.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.7.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.7.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.7.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.7.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.7.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.7.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.7.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.7.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.7.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.7.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.7.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.7.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.7.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.7.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.7.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.8. France
      • 8.3.8.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.8.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.8.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.8.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.8.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.8.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.8.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.8.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.8.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.8.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.8.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.8.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.8.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.8.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.8.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.8.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.9. Spain
      • 8.3.9.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.9.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.9.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.9.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.9.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.9.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.9.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.9.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.9.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.9.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.9.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.9.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.9.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.9.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.9.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.9.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.10. Italy
      • 8.3.10.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.10.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.10.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.10.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.10.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.10.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.10.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.10.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.10.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.10.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.10.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.10.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.10.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.10.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.10.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.10.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.11. Russia
      • 8.3.11.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.11.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.11.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.11.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.11.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.11.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.11.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.11.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.11.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.11.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.11.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.11.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.11.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.11.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.11.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.11.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.12. Turkey
      • 8.3.12.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.12.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.12.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.12.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.12.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.12.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.12.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.12.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.12.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.12.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.12.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.12.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.12.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.12.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.12.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.12.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.13. Austria
      • 8.3.13.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.13.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.13.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.13.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.13.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.13.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.13.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.13.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.13.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.13.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.13.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.13.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.13.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.13.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.13.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.13.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.14. Belgium
      • 8.3.14.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.14.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.14.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.14.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.14.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.14.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.14.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.14.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.14.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.14.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.14.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.14.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.14.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.14.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.14.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.14.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.15. Bulgaria
      • 8.3.15.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.15.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.15.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.15.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.15.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.15.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.15.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.15.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.15.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.15.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.15.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.15.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.15.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.15.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.15.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.15.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.16. Czech Republic
      • 8.3.16.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.16.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.16.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.16.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.16.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.16.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.16.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.16.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.16.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.16.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.16.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.16.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.16.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.16.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.16.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.16.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.17. Denmark
      • 8.3.17.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.17.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.17.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.17.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.17.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.17.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.17.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.17.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.17.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.17.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.17.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.17.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.17.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.17.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.17.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.17.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.18. Finland
      • 8.3.18.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.18.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.18.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.18.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.18.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.18.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.18.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.18.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.18.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.18.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.18.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.18.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.18.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.18.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.18.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.18.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.19. Greece
      • 8.3.19.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.19.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.19.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.19.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.19.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.19.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.19.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.19.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.19.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.19.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.19.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.19.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.19.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.19.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.19.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.19.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.20. Hungary
      • 8.3.20.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.20.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.20.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.20.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.20.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.20.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.20.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.20.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.20.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.20.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.20.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.20.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.20.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.20.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.20.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.20.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.21. Ireland
      • 8.3.21.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.21.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.21.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.21.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.21.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.21.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.21.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.21.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.21.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.21.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.21.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.21.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.21.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.21.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.21.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.21.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.22. Netherlands
      • 8.3.22.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.22.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.22.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.22.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.22.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.22.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.22.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.22.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.22.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.22.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.22.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.22.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.22.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.22.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.22.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.22.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.23. Norway
      • 8.3.23.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.23.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.23.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.23.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.23.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.23.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.23.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.23.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.23.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.23.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.23.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.23.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.23.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.23.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.23.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.23.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.24. Romania
      • 8.3.24.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.24.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.24.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.24.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.24.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.24.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.24.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.24.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.24.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.24.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.24.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.24.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.24.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.24.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.24.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.24.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.25. Slovakia
      • 8.3.25.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.25.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.25.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.25.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.25.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.25.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.25.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.25.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.25.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.25.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.25.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.25.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.25.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.25.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.25.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.25.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.26. Slovenia
      • 8.3.26.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.26.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.26.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.26.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.26.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.26.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.26.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.26.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.26.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.26.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.26.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.26.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.26.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.26.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.26.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.26.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.27. Sweden
      • 8.3.27.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.27.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.27.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.27.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.27.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.27.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.27.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.27.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.27.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.27.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.27.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.27.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.27.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.27.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.27.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.27.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.3.28. Switzerland
      • 8.3.28.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.3.28.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.28.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.3.28.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.3.28.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.3.28.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.3.28.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.3.28.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.3.28.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.3.28.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.3.28.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.3.28.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.3.28.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.3.28.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.3.28.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.3.28.4. Market size, by technology, 2014 - 2025 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Market size, by country, 2014 - 2025 (USD Million)
    • 8.4.2. Market size, by product, 2014 - 2025 (USD Million)
      • 8.4.2.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.2.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
      • 8.4.2.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.2.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
        • 8.4.2.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.2.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
    • 8.4.3. Market size, by application, 2014 - 2025 (USD Million)
      • 8.4.3.1. Market size, by hematology, 2014 - 2025 (USD Million)
      • 8.4.3.2. Market size, by oncology, 2014 - 2025 (USD Million)
        • 8.4.3.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.4.3.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
        • 8.4.3.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
        • 8.4.3.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
    • 8.4.4. Market size, by manufacturer, 2014 - 2025 (USD Million)
    • 8.4.5. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.6. China
      • 8.4.6.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.6.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.6.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.4.6.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.6.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.6.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.6.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.4.6.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.6.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.6.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.6.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.6.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.6.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.6.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
        • 8.4.6.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
        • 8.4.6.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.7. Japan
      • 8.4.7.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.7.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.7.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.7.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.7.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.4.7.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.7.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.7.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.7.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.7.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.7.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.7.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.7.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.7.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.8. India
      • 8.4.8.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.8.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.8.1.1.1. Market size, by interferon, 2014 - 2025 (USD Million)
        • 8.4.8.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.8.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.8.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.8.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
      • 8.4.8.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.8.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.8.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.8.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.8.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.8.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.8.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.8.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.8.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.9. South Korea
      • 8.4.9.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.9.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.9.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.9.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.4.9.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.9.2.1. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.9.2.1.1. Market size, by leukemia, 2014 - 2025 (USD Million)
        • 8.4.9.2.2. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.9.2.2.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.9.2.2.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
      • 8.4.9.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.9.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.10. Australia
      • 8.4.10.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.10.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.10.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.10.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
          • 8.4.10.1.2.2. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
          • 8.4.10.1.2.3. Market size, by follitropin, 2014 - 2025 (USD Million)
        • 8.4.10.2. Market size, by application, 2014 - 2025 (USD Million)
          • 8.4.10.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
          • 8.4.10.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
            • 8.4.10.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
          • 8.4.10.2.3. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
            • 8.4.10.2.3.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.10.2.3.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
        • 8.4.10.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
        • 8.4.10.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.11. New Zealand
      • 8.4.11.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.11.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.11.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.11.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
      • 8.4.11.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.11.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.11.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.11.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.4.11.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.11.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.12. Singapore
      • 8.4.12.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.12.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.12.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.12.1.2.1. Market size, by monoclonal antibodies, 2014 - 2025 (USD Million)
      • 8.4.12.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.12.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.12.2.2. Market size, by autoimmune disease, 2014 - 2025 (USD Million)
          • 8.4.12.2.2.1. Market size, by arthritis, 2014 - 2025 (USD Million)
          • 8.4.12.2.2.2. Market size, by inflammatory bowel disease, 2014 - 2025 (USD Million)
        • 8.4.12.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
        • 8.4.12.4. Market size, by technology, 2014 - 2025 (USD Million)
    • 8.4.13. Malaysia
      • 8.4.13.1. Market size, by product, 2014 - 2025 (USD Million)
        • 8.4.13.1.1. Market size, by recombinant non-glycosylated proteins, 2014 - 2025 (USD Million)
        • 8.4.13.1.2. Market size, by recombinant glycosylated proteins, 2014 - 2025 (USD Million)
          • 8.4.13.1.2.1. Market size, by erythropoietin, 2014 - 2025 (USD Million)
      • 8.4.13.2. Market size, by application, 2014 - 2025 (USD Million)
        • 8.4.13.2.1. Market size, by hematology, 2014 - 2025 (USD Million)
        • 8.4.13.2.2. Market size, by oncology, 2014 - 2025 (USD Million)
          • 8.4.13.2.2.1. Market size, by leukemia, 2014 - 2025 (USD Million)
      • 8.4.13.3. Market size, by manufacturer, 2014 - 2025 (USD Million)
      • 8.4.13.4. Market size, by technology, 2014 - 2025 (USD Million)

Chapter 9. Company Profiles

  • 9.1. 3SBio
    • 9.1.1. Business overview
    • 9.1.2. Financial data
    • 9.1.3. Product landscape
    • 9.1.4. Strategic outlook
    • 9.1.5. SWOT analysis
  • 9.2. Amgen
    • 9.2.1. Business overview
    • 9.2.2. Financial data
    • 9.2.3. Product landscape
    • 9.2.4. Strategic outlook
    • 9.2.5. SWOT analysis
  • 9.3. Biocon
    • 9.3.1. Business overview
    • 9.3.2. Financial data
    • 9.3.3. Product landscape
    • 9.3.4. Strategic outlook
    • 9.3.5. SWOT analysis
  • 9.4. Biogen
    • 9.4.1. Business overview
    • 9.4.2. Financial data
    • 9.4.3. Product landscape
    • 9.4.4. Strategic outlook
    • 9.4.5. SWOT analysis
  • 9.5. Boehringer Ingelheim
    • 9.5.1. Business overview
    • 9.5.2. Financial data
    • 9.5.3. Product landscape
    • 9.5.4. Strategic outlook
    • 9.5.5. SWOT analysis
  • 9.6. Celltrion
    • 9.6.1. Business overview
    • 9.6.2. Financial data
    • 9.6.3. Product landscape
    • 9.6.4. Strategic outlook
    • 9.6.5. SWOT analysis
  • 9.7. Coherus BioSciences
    • 9.7.1. Business overview
    • 9.7.2. Financial data
    • 9.7.3. Product landscape
    • 9.7.4. Strategic outlook
    • 9.7.5. SWOT analysis
  • 9.8. Dr. Reddy's Laboratories
    • 9.8.1. Business overview
    • 9.8.2. Financial data
    • 9.8.3. Product landscape
    • 9.8.4. Strategic outlook
    • 9.8.5. SWOT analysis
  • 9.9. Elli Lilly and Company
    • 9.9.1. Business overview
    • 9.9.2. Financial data
    • 9.9.3. Product landscape
    • 9.9.4. Strategic outlook
    • 9.9.5. SWOT analysis
  • 9.10. Intas Biopharmaceuticals
    • 9.10.1. Business overview
    • 9.10.2. Financial data
    • 9.10.3. Product landscape
    • 9.10.4. Strategic outlook
    • 9.10.5. SWOT analysis
  • 9.11. Lupin
    • 9.11.1. Business overview
    • 9.11.2. Financial data
    • 9.11.3. Product landscape
    • 9.11.4. Strategic outlook
    • 9.11.5. SWOT analysis
  • 9.12. Merck
    • 9.12.1. Business overview
    • 9.12.2. Financial data
    • 9.12.3. Product landscape
    • 9.12.4. Strategic outlook
    • 9.12.5. SWOT analysis
  • 9.13. Novartis (Sandoz)
    • 9.13.1. Business overview
    • 9.13.2. Financial data
    • 9.13.3. Product landscape
    • 9.13.4. Strategic outlook
    • 9.13.5. SWOT analysis
  • 9.14. Ratiopharm
    • 9.14.1. Business overview
    • 9.14.2. Financial data
    • 9.14.3. Product landscape
    • 9.14.4. Strategic outlook
    • 9.14.5. SWOT analysis
  • 9.15. Samsung Bioepis
    • 9.15.1. Business overview
    • 9.15.2. Financial data
    • 9.15.3. Product landscape
    • 9.15.4. Strategic outlook
    • 9.15.5. SWOT analysis
  • 9.16. Sanofi
    • 9.16.1. Business overview
    • 9.16.2. Financial data
    • 9.16.3. Product landscape
    • 9.16.4. Strategic outlook
    • 9.16.5. SWOT analysis
  • 9.17. STADA Arzneimittel
    • 9.17.1. Business overview
    • 9.17.2. Financial data
    • 9.17.3. Product landscape
    • 9.17.4. Strategic outlook
    • 9.17.5. SWOT analysis
  • 9.18. Teva Pharmaceutical
    • 9.18.1. Business overview
    • 9.18.2. Financial data
    • 9.18.3. Product landscape
    • 9.18.4. Strategic outlook
    • 9.18.5. SWOT analysis
  • 9.19. Wockhardt
    • 9.19.1. Business overview
    • 9.19.2. Financial data
    • 9.19.3. Product landscape
    • 9.19.4. Strategic outlook
    • 9.19.5. SWOT analysis
  • 9.20. Zydus Cadila
    • 9.20.1. Business overview
    • 9.20.2. Financial data
    • 9.20.3. Product landscape
    • 9.20.4. Strategic outlook
    • 9.20.5. SWOT analysis